Investors

Company Directors

Board of Directors

Tim McCarthy (Executive Chairman)
21.08.56

Tim has more than 35 years’ international senior level business experience in the Healthcare, Biotech and Technology sectors.

He is also the Non-Executive Chairman of ImmuPharma plc, an AIM quoted specialist drug discovery and development company and of 4basebio UK Societas, an AIM quoted company developing next generation gene therapy technologies and solutions. 

Tim is a former CEO and Finance Director of a number of public and private companies, including Alizyme plc and Peptide Therapeutics Group plc. He has also co-founded a number of healthcare and biotechnology companies. A Fellow of the Association of Chartered Certified Accountants, he also has an MBA from Cranfield School of Management.

Dr Simon Ward (Chief Executive Officer)
7.10.68

Simon is a co-founder of Incanthera and has more than 30 years’ senior experience in academia and business.

He was a founder and CEO of Molecular SkinCare Limited, a pioneer and developer of novel dermatology products for the prevention and management of skin diseases. As CSO of York Pharma plc, he was responsible for bringing innovative dermatology product through to market. Simon also served as chairman of South Yorkshire Bioscience Enterprise Network (SYBEN) and deputy chairman of Medipex, a healthcare innovation hub for NHS organisations across industry and academia internationally.

Simon graduated from the University of London’s School of Pharmacy (UK) with a Joint Honours Degree in Pharmacology and Toxicology and was awarded a DPhil in the Department of Human Anatomy, Oxford University under a Glaxo Group Research Studentship.

Dr Alan Warrander (Independent Non-executive Director)
8.10.52

Alan is an expert in partnering and licensing with significant experience of global pharma drug discovery and drug development processes having more than 30 years’ experience in the Pharmaceutical Industry, including 21 years with AstraZeneca, holding many positions including Director of Global Licensing.

He has a BSc in Chemistry and Biochemistry and a PhD in Biochemistry.

Key Senior Management

Pawel Zolnierczyk (Chief Operating Officer)

Pawel has over ten years’ experience inresearch commercialisation in the life sciences sector successfully managing IP exploitation projects toward licences and spin-offs.

He was the founder and Managing Director of Onco-NX (acquired by Incanthera in 2014); CEO of iTech Innovations Ltd. Formerly as IP Manager for the University of Salford, Pawel successfully negotiated deals with corporate partners including Reckitt Benckiser plc and Novartis AG.

Pawel is a graduate of Gdansk University of Technology.

Laura Jane Brogden (Chief Financial Officer)

Laura Brogden has 20 years’ experience heading up the finance function for SMEs across a diverse range of industries

She is also a Partner in Fact3 LLP which provides accounting, HR and IT support for SMEs.

Laura is an Associate of the Chartered Institute of Management Accountants.

Suzanne Brocks (Head of Communications & Company Secretary)

Suzanne has over 30 years’ City experience.

She was a Senior Director in Financial and Corporate Communications with Buchanan Communications, advising on IPOs and mergers and acquisitions, in addition to general financial public relations consultancy and strategic direction for a wide range of public companies. Previously Suzanne was a Relationship Manager in private banking with Hill Samuel advising clients in London and the Far East.